US2019275120A1 (Synthetic Biologics) claims a method for treating or preventing infection (CDI) in patients determined to be resistant to an antibiotic, consisting of administering an effective amount of a beta-lactamase before or concurrently with the antibiotic or a different antibiotic [70]. This evidence concerns the gene LACTB and clostridium difficile infection.